Laigo Bio
PrivateLast Round
Seed
Mar 23, 2026
Total Funding Raised
$31.5M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Laigo Bio operates in Healthcare & Life Sciences and is based in Utrecht. Its latest recorded funding round was a Seed round in March 2026.
Laigo Bio is a biotechnology company that develops bispecific antibody-based therapeutics for oncology and immunology using its proprietary SureTAC™ precision membrane protein degradation platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Laigo Bio Comparables
Compare Laigo Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| GlycoEra | 82% | |
| Avilar Therapeutics | 81% | |
| Johnson & Johnson | 80% |
For institutional investors. Book with your work email.
Laigo Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Mar 23, 2026 | ||||
| Seed | Dec 4, 2025 | ||||
| Seed | Feb 8, 2022 |
For institutional investors. Book with your work email.
Laigo Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Cancer Research Horizons | Seed |
| ROM Utrecht Region | Seed |
| Oncode Institute | Seed |
| Biovance Capital Partners | Seed |
| Angelini Ventures | Seed |
| Cancer Research Horizons | Seed |
| Eurazeo | Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 1, 2026
Grew 22% QoQ, from 18 to 22 employees.
- Jun 23, 2026
Grew 33% QoQ from 15 to 20 employees.
For institutional investors. Book with your work email.
Laigo Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Laigo Bio's valuation, stock price, and market status.
Is Laigo Bio a public or private company?
Laigo Bio is a private company.
What is the current stock price of Laigo Bio?
Laigo Bio is a private company, so its shares have no public market price. Caplight tracks Laigo Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Laigo Bio worth (valuation)?
Valuation information for Laigo Bio is not publicly available.
Can I buy Laigo Bio stock?
Laigo Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Laigo Bio's last funding round?
Laigo Bio's most recent funding round was Seed on March 23, 2026.
Who are the main investors in Laigo Bio?
Key investors in Laigo Bio include Biovance Capital Partners, Kurma Partners, Curie Capital.
Will Laigo Bio IPO soon?
No public IPO plans have been announced for Laigo Bio.
How can I track Laigo Bio secondary market activity?
Caplight tracks bids, offers, and trades in Laigo Bio's shares on secondary markets.